Application of gRNA (guide Ribonucleic Acid) for inhibiting pig C16orf62 gene expression in preparation of medicine for resisting pig delta coronavirus infection

By knocking out the pig C16orf62 gene in LLC-PK1 cells, using CRISPR/Cas9 technology to inhibit the proliferation of PDCoV, the problem of lack of effective treatment and understanding of the mechanism of pig delta coronavirus infection is solved, and new disease-resistant targets and vaccine development are provided. In order to achieve effective resistance to PDCoV infection.

CN118910049AActive Publication Date: 2024-11-08HUAZHONG AGRI UNIV

Patent Information

Application Number
CN202410972667.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

At present, no effective therapeutic drugs or vaccines specifically targeting pig delta coronavirus (PDCoV) infection have been developed, and there is little knowledge of the mechanism of PDCoV infection. Existing studies have shown that ANPEP knockdown of the receptor gene of PDCoV cannot completely prevent viral infection, suggesting other Receptors or auxiliary receptors are involved in the infection process and need to analyze the mechanism of coronavirus infection to develop broad-spectrum antiviral drugs.

Method used

By knocking out the pig C16orf62 gene in LLC-PK1 cells, using the CRISPR/Cas9 gene editing system to design gRNA that inhibits the expression of pig C16orf62 gene, and constructing a mutant cell line that inhibits the expression of the C16orf62 gene. It was found that this gene knockout can inhibit the pig δ coronavirus Proliferation, thus providing new disease-resistant targets and vaccine development directions.

Benefits of technology

It was first discovered that C16orf62 gene knockout can resist PDCoV infection, providing new targets and candidate genes, providing new strategies for the development of effective anti-PDCoV vaccines and drugs, and has broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910049A_ABST
    Figure CN118910049A_ABST
Patent Text Reader

Abstract

The invention discloses application of gRNA (guide Ribonucleic Acid) for inhibiting pig C16orf62 gene expression in preparation of a medicine for resisting pig delta coronavirus infection, and belongs to the field of gene engineering and biological medicine. A pig C16orf62 gene knockout cell line is constructed based on a CRISPR / Cas9 knockout technology, and it is found that the pig C16orf62 gene can inhibit proliferation of the pig delta coronavirus after being knocked out in LLC-PK1 cells, so that the gene can serve as a novel target for development of vaccine drugs for inhibiting replication of the pig delta coronavirus and research on disease resistance breeding; and a new method and direction are provided for prevention and control of the porcine delta coronavirus and diseases caused by the porcine delta coronavirus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of genetic engineering and biomedicine, and in particular to the use of gRNA for inhibiting the expression of porcine C16orf62 gene in the preparation of drugs for resisting porcine delta coronavirus infection. Background Art

[0002] Porcine deltacoronavirus (PDCoV) is one of the pathogens that causes severe diarrhea and death in piglets. The virus has posed a serious threat to the global pig industry and caused huge economic losses. The virus was first reported by Hong Kong scientists in 2012, but the virus was not isolated. In early 2014, PDCoV was first detected in pig farms in the United States, and then in pig farms in South Korea, Canada and other countries. Professor Hu Hui first used porcine testicular cells (ST) and porcine kidney cells (LLC-PK1) to isolate PDCoV from fecal samples and intestinal samples of sick pigs. Although the successful isolation of PDCoV has greatly promoted the basic and applied research progress of the virus, no effective therapeutic drugs or vaccines specifically for the virus infection have been developed, and the mechanism of PDCoV infection is still poorly understood. Previous studies have shown that the knockout of the PDCoV receptor gene ANPEP cannot completely prevent the virus infection, suggesting that other receptors or co-receptors are involved in the virus infection process. The analysis of the infection mechanism of coronavirus to the host is of great significance for the development of broad-spectrum antiviral drugs.

[0003] After coronavirus binds to cell surface receptors, it releases its genome into the cytoplasm to initiate the replication process mainly through two pathways: first, the virus can directly fuse its envelope with the cell membrane to invade the cell; second, the virus particles may also enter the cell through the endocytosis pathway, complete the fusion of the viral envelope and the endosomal membrane in the early endosome, late endosome or lysosome, and then release its genome for replication. When the receptor on the cell surface is bound by the cell or virus-derived ligand, the cell's endocytosis process will be initiated. The fate of the internalized receptor and complex will be determined by the transport complex such as the retromer (also known as Retromer, composed of VPS26, VPS29 and VPS35). A part of the receptor and complex is mediated by the recycling endosome and transported along the microtubules, and finally returns to the plasma membrane, trans-Golgi apparatus or the virus replication area to exert its physiological function. Another part passes through the early endosome and continues to be transported to the late endosome or lysosome, and is eventually degraded or completes the release of the viral genome. Retriever is a new type of trimeric complex, which is similar in structure and function to the Retromer complex. It is composed of C16orf62, VPS26 and VPS29, and is called the heterologous reverse vesicle transport complex. Both complexes are located in the same endosomal domain and are associated with sorting junction proteins for specific cargo selection, sorting transmembrane cargo from the endolysosomal pathway back to the cell surface. The role of Retromer in viral infection is relatively clear. It can interact with a variety of viral proteins or viral receptors, thereby affecting viral invasion, infection and viral replication. For example, hepatitis C virus (HCV), human papillomavirus (HPV), SARS CoV-2, etc. However, the mechanism of action of Retriever in viral infection is relatively less studied.

[0004] In order to identify the receptors and infection-related host factors of PDCoV, a CRISPR / Cas9 high-throughput screening platform was established in PDCoV susceptible cells Huh7, and the receptors and infection-related host factors of PDCoV were screened using this technology. Through this platform, the present invention found that the key gene C16orf62 (also known as VPS35L) of the Retriever complex was significantly enriched in the PDCoV infection group, and there is currently no report on the involvement of C16orf62 in coronavirus infection. Summary of the invention

[0005] The purpose of the present invention is to provide an application of gRNA for inhibiting the expression of porcine C16orf62 gene in the preparation of an anti-porcine delta coronavirus infection drug to solve the problems existing in the above-mentioned prior art. By knocking out the porcine C16orf62 gene in LLC-PK1 cells, it was found that the proliferation of porcine delta coronavirus can be inhibited, which provides a new strategy for preventing and controlling porcine delta coronavirus and the diseases caused by it.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides a gRNA for inhibiting the expression of pig C16orf62 gene, wherein the nucleotide sequence of the gRNA is: 5'-CAAAGAAAGTGAGCCGGAAG-3'.

[0008] The present invention also provides a knockout vector or a knockout cell line containing the gRNA.

[0009] The present invention also provides a kit containing the gRNA.

[0010] Preferably, the kit further comprises a primer pair for detecting the expression of porcine C16orf62 gene.

[0011] The present invention also provides the use of the gRNA or the knockout vector or the knockout cell line or the kit in any of the following:

[0012] (1) Application in identifying the function of the porcine C16orf62 gene;

[0013] (2) Application in the preparation of drugs or cell models against porcine delta coronavirus infection;

[0014] (3) Application in the preparation of drugs for inhibiting the proliferation of porcine delta coronavirus in LLC-PK1 cells.

[0015] The present invention also provides a method for constructing a mutant cell strain that inhibits the expression of the porcine C16orf62 gene, comprising taking the porcine C16orf62 gene as a target gene, knocking out the C16orf62 gene in the cell using the CRISPR / Cas9 gene editing system, and constructing a mutant cell strain that inhibits the expression of the C16orf62 gene;

[0016] The gRNA sequence of the CRISPR / Cas9 gene editing system is 5'-CAAAGAAAGTGAGCCGGAAG-3', and the nucleotide sequence of the C16orf62 gene is the sequence shown in SEQ ID NO.1 or a gene sequence containing the sequence shown in SEQ ID NO.1.

[0017] Preferably, the cells comprise porcine cells.

[0018] Preferably, the pig cells are pig kidney cells.

[0019] The present invention also provides a mutant cell strain for inhibiting the expression of pig C16orf62 gene, which is constructed by the construction method.

[0020] The present invention also provides the use of the mutant cell strain in screening targets or drugs for inhibiting the proliferation of porcine delta coronavirus.

[0021] The present invention discloses the following technical effects:

[0022] The present invention uses CRISPR / Cas9 knockout technology to knock out C16orf62 in LLC-PK1 cells, and for the first time finds that cells knocked out C16orf62 can resist PDCoV infection by inhibiting the proliferation of PDCoV, and this gene can be used as a new anti-disease target for PDCoV. The present invention provides a new target for the development of a new vaccine drug that effectively and safely prevents and treats PDCoV, and also provides a new candidate target gene for breeding research against PDCoV, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 To design gRNA targeting porcine C16orf62 gene;

[0025] Figure 2 To construct a knockout plasmid map targeting the porcine C16orf62 gene;

[0026] Figure 3 This is the electrophoresis diagram of bacterial solution PCR identification of plasmid construction; M is Trans 2K Plus DNA Marker, 1-5 are sgLenti-C16orf62 KO sgRNA bacterial solution, and 6 is a negative control;

[0027] Figure 4 The results of successful plasmid construction were verified by sequencing;

[0028] Figure 5 Western Blot test of the successful construction of LLC-PK1 Cas9 cell line

[0029] Figure 6 The results of the construction and verification of LLC-PK1 Cas9-C16orf62 KO monoclonal cell line; (A) DNA sequencing of C16orf62 gene sequences in NC KO and C16orf62 KO cells; (B) CCK-8 assay to detect the activity of NC KO cells and C16orf62KO cells;

[0030] Figure 7 After DAPI staining, fluorescence microscopy was used to observe the effect of C16orf62 knockout on PDCoV infection;

[0031] Figure 8 To analyze the effect of C16orf62 knockout on PDCoV infection by flow cytometry;

[0032] Fig. 9 To count the proportion of PDCoV-infected cells after knocking out C16orf62, (*P<0.05, **P<0.01, ***P<0.01, t-test);

[0033] Fig.10 qRT-PCR analysis of the effect of knocking out C16orf62 on PDCoV infection;

[0034] Fig.11 The growth curve of PDCoV in NC KO and C16orf62 KO cells. DETAILED DESCRIPTION

[0035] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0036] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0037] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0038] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0039] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0040] Example 1 Construction and verification of C16orf62 knockout cell line

[0041] The NCBI number of the mRNA of the target gene C16orf62 gene is NC_010445.4, the corresponding CDS sequence is shown in SEQ ID NO.1, and it encodes the protein shown in SEQ ID NO.2.

[0042] CDS Sequence:

[0043]

[0044] Amino Acid Sequence:

[0045] 。

[0046] 1. gRNA design and expression vector construction

[0047] (1) gRNA design: Select the partial sequence of the gene location where the gRNA is required to target, and design the sequence of the knockout gRNA. Figure 1 ; gRNA: 5'-CAAAGAAAGTGAGCCGGAAG-3' (SEQ ID NO. 5).

[0048] (2) Anneal the single-stranded gRNA synthesized by the company into double-stranded gRNA. The annealing system: 10 μL of upstream and downstream sgRNA, 2.5 μL of ddH2O, 2.5 μL of T4 Buffer, 1 μL of polynucleotide 5' hydroxykinase (PNK); the procedure is as follows: 37°C for 30 min, 95°C for 5 min, 80°C for 5 min, 75°C for 5 min, 70°C for 5 min, and 20°C for 5 min.

[0049] (3) The sgLenti (MP-783) (Tromp, et al., 2018, “Human CD45 is an F-component-specific receptor for the staphylococcal toxin Panton-Valentine leukocidin”) vector was digested with Aar I and then ligated with gRNA to the vector using T4 ligase to construct a knockout vector.

[0050] (4) Transform the vector into DH5α, plate the plate, pick the single clone colony, use the 2×Es TaqMasterMix (Dye) enzyme of Kangwei Century Company for PCR amplification and send it to the company for sequencing verification. The amplification primers are: F: 5'-ATAACTTCGTATAGCATACATTAT-3'; R: 5'-GCACATGCAGTGACTGGAGT-3'. Set the PCR system: 2×EsTaq MasterMix (Dye) 12.5μL, 1μL of upstream and downstream primers, 2μL of template, 8.5μL of ddH2O. The procedure is as follows: pre-denaturation at 94℃ for 2min, cycle reaction is denaturation at 94℃ for 30sec, annealing at 56℃ for 30sec, extension at 72℃ for 30sec, a total of 35 cycles, and finally extension at 72℃ for 2min. The PCR product was sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing.

[0051] (5) The correct positive colonies were verified by PCR and sequencing (see Figure 3 and Figure 4), according to the instructions of the plasmid extraction kit (DP103) of TIANGEN, the plasmid was extracted from the expanded bacterial solution, and the obtained plasmid was named sgLenti-C16orf62 KO vector (see the map) Figure 2 ).

[0052] like Figure 1-Figure 4 As shown, the results showed that the gRNA targeting the C16orf62 gene was successfully connected to the plasmid, indicating that the gRNA expression vector was successfully constructed.

[0053] 2. Construction of LLC-PK1 Cas9 cell line

[0054] According to the operating instructions of the DNA transfection reagent (114-15) of jetPRIME, the lentivirus pLenti-Cas9-Blast (Addgene, 52962) was packaged using auxiliary plasmids psPax2 (Addgene, 12260) and pMD2.G (Addgene, 12259).

[0055] LLC-PK1 (purchased from the cell bank of the Chinese Academy of Sciences) cells were inoculated into 24-well cell culture plates and divided into a transduction group and a control group. When the cell confluence reached 40% to 50%, the pLenti-Cas9-Blast lentivirus (MOI = 1) was diluted with DMEM high-glucose medium containing 10% FBS, 1% penicillin-streptomycin and 8μg / mL polybrene, and transduced into LLC-PK1 cells. After 1 day, it was replaced with fresh complete medium and continued to be cultured. After 2 days, it was replaced with a complete medium containing 6μg / mL blasticidin (Blasticidin, Blast) for screening. When all cells in the control group died, the surviving cells in the experimental group were inoculated into a 96-well cell plate by multiple dilution to form a single cell, and continued to be cultured with Blast medium. When the single cell grew into a monoclonal cell cluster, it was digested with trypsin and placed in a 24-well culture plate for expansion culture to obtain a monoclonal cell line LLC-PK1 Cas9, and western blot was performed to detect the expression of Cas9:

[0056] (1) Preparation of protein samples: LLC-PK1 cells and LLC-PK1 Cas9 cell lines were evenly plated in 6-well plates. When the cells grew into a monolayer, the culture medium was discarded and the cells were washed twice with pre-cooled PBS.

[0057] (2) Add lysis buffer containing PMSF and protease inhibitors (abcam, ab141032) to each well and lyse on ice for 15 min. Scrape the cells with a cell scraper and pipette the lysate into a 1.5 mL centrifuge tube. Use a 1 mL syringe to blow repeatedly until clear. Add 5× SDS-PAGE loading buffer and boil in a metal bath at 95°C for 10 min before loading and detection.

[0058] (3) Perform SDS-PAGE electrophoresis.

[0059] (4) Perform Western Blot analysis:

[0060] a) The primary antibody was Cas9 Rabbit pAb (ABclonal, A14997), and the secondary antibody was HRP-conjugated Goat anti-Rabbit IgG (H+L) (ABclonal, AS014).

[0061] b) Protein detection: ECL luminescence method was used.

[0062] The results are as follows Figure 5 As shown, Western Blot detection found that LLC-PK1 Cas9 cells expressed Cas9 protein, while the control group LLC-PK1 cell line did not express Cas9 protein, indicating that LLC-PK1 Cas9 cells were successfully constructed.

[0063] 3. Construction of C16orf62 knockout monoclonal cell line

[0064] (1) According to the operating instructions of the DNA transfection reagent (114-15) of jetPRIME, auxiliary plasmids psPax2 (Addgene, 12260) and pMD2.G (Addgene, 12259) were used to package lentiviral gRNA.

[0065] (2) LLC-PK1 Cas9 cells were seeded into 24-well cell culture plates and divided into a transduction group and a control group. They were cultured in DMEM high-glucose medium containing 10% FBS and 1% penicillin-streptomycin.

[0066] (3) When the cell confluence reached 40% to 50%, the gRNA lentivirus targeting the gene C16orf62 (MOI = 1) was diluted with DMEM high-glucose medium containing 10% FBS, 1% penicillin-streptomycin and 8 μg / mL polybrene and transduced into LLC-PK1 Cas9 cells.

[0067] (4) One day after infection, replace the culture medium with fresh complete medium and continue culturing.

[0068] (5) After 2 days of infection, the culture medium was replaced with complete culture medium (10% FBS, 1% penicillin-streptomycin DMEM high-glucose medium) containing 4 μg / mL puromycin.

[0069] (6) Replace the culture medium containing puromycin with fresh one every day. When all cells in the control group have died and there are cells in the experimental group surviving, dilute the cells in the experimental group and inoculate them into a 96-well cell plate to form single cells. Continue to culture them with the culture medium containing puromycin.

[0070] (7) The culture was continued for about 7 days until the single cells grew into monoclonal cell clusters. The monoclonal cells were selected, digested with trypsin, and placed in a 24-well culture plate to obtain a monoclonal cell line (C16orf62 KO).

[0071] 4. Verification of C16orf62 gene expression and cell activity in C16orf62 KO cell lines

[0072] 4.1 Detection of C16orf62 gene DNA editing in C16orf62 KO monoclonal cells by genomic DNA sequencing

[0073] (1) Extraction of cell genomic DNA

[0074] According to the operating instructions of Tiangen DNA Extraction Kit (DP304), DNA was extracted from the C16orf62 knockout monoclonal cell line and the control group LLC-PK1 Cas9 cells (referred to as NC KO cells).

[0075] (2) To verify the sequence near the C16orf62 gene knockout site, PCR amplification was performed using PrimeSTARMax DNA Polymerase (R045Q) provided by Takara, and the samples were sent for sequencing. The amplification primers were:

[0076] C16orf62 KO-F: 5'-AGTGGCCGTGTCGCTCCCTT-3';

[0077] C16orf62 KO-R: 5'-GGAAGCAGCAGCAGTTTCCAGGATCTA-3'.

[0078] The PCR program was set as follows: pre-denaturation at 98°C for 15 seconds, cycle reaction of denaturation at 98°C for 10 seconds, annealing at 55°C for 15 seconds, extension at 72°C for 1 minute, a total of 35 cycles, and final extension at 72°C for 5 minutes. The PCR products were sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing.

[0079] The sequencing results are as follows Figure 6As shown in A, it was found that the C16orf62 KO monoclonal cell line had a frameshift mutation in the C16orf62 gene due to a deletion of 7 base pairs, and thus no C16orf62 protein was produced.

[0080] The amplified sequence of the NC KO cells before knockout is shown in SEQ ID NO.3; the amplified sequence of the C16orf62 KO monoclonal cell line after knockout is shown in SEQ ID NO.4.

[0081] SEQ ID NO.3 is:

[0082] .

[0083] SEQ ID NO.4 is:

[0084] .

[0085] 4.2 Detection of the activity of C16orf62 KO monoclonal cell line using CCK-8 method

[0086] (1) Cell viability was detected according to the instructions of the CCK-8 kit (Biyuntian, C0037). NC KO cells and C16orf62 KO cells were inoculated into 96-well plates, with 3 replicates for each group of cells, and cultured in a 5% CO2, 37°C incubator for 48 h.

[0087] (2) Take out the 96-well plate, add 10 μL of CCK-8 solution to each well, and continue incubating in the cell culture incubator for 4 h.

[0088] (3) Use an ELISA reader to measure the absorbance at 450 nm.

[0089] The results of CCK-8 experiment are as follows Figure 6 As shown in B, the results showed that there was no difference in cell viability before and after C16orf62 knockout, indicating that knocking out the C16orf62 gene had no significant effect on cell activity.

[0090] Example 2 Detection of the effect of LLC-PK1 cell knockout of C16orf62 gene on PDCoV infection

[0091] Fluorescence microscopy, flow cytometry and qRT-PCR were used to detect the inhibitory effect of LLC-PK1 cell knockout of C16orf62 gene on PDCoV infection. The specific operations are as follows:

[0092] C16orf62 KO cells and control cells NC KO were inoculated into 24-well plates and cultured in a 5% CO2, 37°C incubator. After 24 hours, the culture medium was discarded, washed three times with PBS, and replaced with PDCoV-GFP virus solution diluted with DMEM medium containing 10 μg / mL trypsin, MOI = 0.1, which was constructed and preserved by this laboratory (refer to Zhang et al, 2020, "Genetic manipulation of porcine deltacoronavirus reveals insights into NS6and NS7 functions: anovel strategy for vaccine design"), incubated at 37°C for 1 hour, washed three times with PBS, and then added with medium containing 10 μg / mL trypsin, and continued to culture. The supernatant was collected 12 hours and 24 hours after infection, respectively, and observed using a fluorescence microscope and analyzed by a popular cytometer, and the virus solution collected at 24 hours was identified by qRT-PCR.

[0093] (1) After DAPI staining, the effect of C16orf62 knockout on PDCoV infection was observed using fluorescence microscopy.

[0094] (2) Flow cytometric analysis was used to detect the effect of C16orf62 knockout on PDCoV infection.

[0095] (3) Fluorescence quantitative detection: First, the viral RNA was extracted using the Tiangen Virus RNA Extraction Kit (YDP315-R), and the cDNA was generated as a template using the Novagen reverse transcription kit HiScript II 1st Strand cDNA Synthesis Kit (R211-01). Amplification was performed using the Takara probe detection kit (RR600B) in a Bio-Rad CFX96 instrument. The standard plasmid was constructed and preserved in the laboratory, the probe sequence was 5'-CACACCAGTCGTTAAGCATGGCAAGCT-3', and the upstream and downstream sequences of the amplification primers were F: 5'-ATCGACCACATGGCTCCAA-3', R: 5'-CAGCTCTTGCCCATGTAGCTT-3'. The reaction system and procedures were performed according to the instructions.

[0096] The results are as follows Figure 7-Figure 10 As shown in the figure, the number of cells infected with PDCoV in C16orf62 KO cells was significantly lower than that in NC KO control cells after 12h and 24h of infection, as analyzed by fluorescence microscopy and flow cytometry. The qRT-PCR results further showed a decrease in the number of PDCoV RNA copies after C16orf62 knockout, indicating that knockout of the C16orf62 gene in LLC-PK1 cells significantly inhibited the proliferation of PDCoV.

[0097] Example 3

[0098] Draw a one-step growth curve using TCID 50 The deletion of C16orf62 gene in LLC-PK1 cells was detected to inhibit the proliferation of PDCoV.

[0099] C16orf62 KO cells and control cells NC KO were inoculated into 24-well plates and cultured at 5% CO2 and 37°C. After 24 hours, the original culture medium was discarded, washed three times with PBS, and then replaced with PDCoV-GFP diluted in DMEM medium containing 10μg / mL trypsin. After incubation at 37°C for 1 hour, it was washed three times with PBS, and then the culture medium containing 10μg / mL trypsin was added and continued to be cultured. The supernatant was collected at 6h, 12h, 24h, 36h and 48h after infection for detection of PDCoV titer. The experiment was repeated 3 times. The specific detection method is as follows.

[0100] (1) LLC-PK1 cells were plated into 96-well plates and allowed to grow into a confluent monolayer.

[0101] (2) The collected virus solution was diluted 10-fold in DMEM containing 10 μg / mL pancreatin, ranging from 10 -1 to 10 -10 .

[0102] (3) Add 100 μL of diluted virus solution to each well. Set up 8 replicate wells for each dilution. At the same time, use DMEM without virus as a blank control.

[0103] (4) The 96-well plate was placed in a 37°C, 5% CO2 incubator and observed every day. After 2-3 days, the number of wells infected with PDCoV was counted.

[0104] (5) Calculated according to the Reed-Muench method: distance ratio = (percentage of lesion rates above 50% - 50%) / (percentage of lesion rates above 50% - percentage of lesion rates below 50%), lgTCID 50= distance ratio × difference between logarithms of dilution + logarithm of dilution with higher than 50% lesion rate.

[0105] The results are as follows Fig.11 As shown, it can be observed from the one-step growth curve that knocking out C16orf62 in LLC-PK1 cells significantly decreased the PDCoV titer, indicating that knocking out this gene in LLC-PK1 cells can inhibit the proliferation of PDCoV.

[0106] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A gRNA for inhibiting the expression of porcine C16orf62 gene, It is characterized in that The nucleotide sequence of the gRNA is: 5'-CAAAGAAAGTGAGCCGGAAG-3'.

2. A knockout vector or knockout cell line containing the gRNA according to claim 1.

3. A kit containing the gRNA according to claim 1.

4. The kit according to claim 3, It is characterized in that The kit also includes a primer pair for detecting the expression of porcine C16orf62 gene.

5. Use of the gRNA according to claim 1, the knockout vector or the knockout cell line according to claim 2, or the kit according to any one of claims 3-4 in any of the following: (1) Application in identifying the function of the porcine C16orf62 gene; (2) Application in the preparation of drugs or cell models against porcine delta coronavirus infection; (3) Application in the preparation of drugs for inhibiting the proliferation of porcine delta coronavirus in LLC-PK1 cells.

6. A method for constructing a mutant cell line that inhibits the expression of porcine C16orf62 gene, It is characterized in that This includes using the porcine C16orf62 gene as a target gene, knocking out the C16orf62 gene in cells using the CRISPR / Cas9 gene editing system, and constructing a mutant cell line that inhibits the expression of the C16orf62 gene; The gRNA sequence of the CRISPR / Cas9 gene editing system is 5'-CAAAGAAAGTGAGCCGGAAG-3', and the nucleotide sequence of the C16orf62 gene is the sequence shown in SEQ ID NO.1 or a gene sequence containing the sequence shown in SEQ ID NO.

1.

7. The construction method according to claim 6, It is characterized in that The cells include porcine cells.

8. The construction method according to claim 7, It is characterized in that The pig cells are pig kidney cells.

9. A mutant cell line that inhibits the expression of porcine C16orf62 gene, It is characterized in that It is constructed by the construction method described in any one of claims 6 to 8.

10. Use of the mutant cell line according to claim 9 in screening targets or drugs for inhibiting the proliferation of porcine delta coronavirus.

Citation Information

Patent Citations

  • Antiviral target gene of coronavirus including SARS-CoV and SARS-CoV-2 and application of antiviral target gene

    CN114057859A

  • Mammalian genes involved in infection

    US20130280806A1

Cited By

  • Application of RBM6 in animal anti-influenza

    CN119633120A

  • Application of RBM6 in animal anti-influenza

    CN119633120B